Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial

Related documents

• How can countries respond to the health and care workforce crisis? Insights from international evidence#1005618
• Management of patients with advanced prostate cancer: Recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015#1005619
• A high-throughput method using Ultra-Performance Liquid Chromatography to determine water-soluble carbohydrate concentrations in pasture plants#1005621
• Malaria case management in Papua New Guinea prior to the introduction of a revised treatment protocol#1005622
• Connectivity-guided, interleaved iTBS-fMRI demonstrates subcortical target engagement in treatment-resistant depression#1005623